よむ、つかう、まなぶ。
会議資料 (87 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00036.html |
| 出典情報 | 医薬・生活衛生局が実施する検討会 医療上の必要性の高い未承認薬・適応外薬検討会議（第62回 3／13）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
要望番号；II-5
over 1 year of age. Eur J Cancer 2008; 44: 551-6.
27. Kanold J, Paillard C, Tchirkov A, Merlin E, Marabelle A, Lutz P, et al. Allogeneic or
haploidentical HSCT for refractory or relapsed solid tumors in children: toward a
neuroblastoma model. Bone Marrow Transplant 2008; 42 Suppl 2: S25-30.
28. Mastrangelo S, Rufini V, Ruggiero A, Di Giannatale A, Riccardi R. Treatment of advanced
neuroblastoma in children over 1 year of age: the critical role of 131I-metaiodobenzylguanidine
combined with chemotherapy in a rapid induction regimen. Pediatr Blood Cancer 2011; 56:
1032-40.
29. Klingebiel T, Bader P, Bares R, Beck J, Hero B, Jürgens H, et al. Treatment of neuroblastoma
stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A
pilot study. Eur J Cancer 1998; 34: 1398-402.
30. Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, et al. Is there a benefit of
131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective
evaluation of The German Neuroblastoma Trial NB97 and implications for The German
Neuroblastoma Trial NB2004. Nuklearmedizin 2006; 45: 145-51; quiz N39-40.
31. Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B, et al. Pilot study of
iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and
autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002; 20: 21429.
32. DuBois SG, Allen S, Bent M, Hilton JF, Hollinger F, Hawkins R, et al. Phase I/II study of
131
I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Br J Cancer
2015; 112: 644-9.
33. Lee JW, Lee S, Cho HW, Ma Y, Yoo KH, Sung KW, et al. Incorporation of high-dose 131Imetaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem
cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. J Hematol
Oncol 2017; 10: 108.
34. Kraal KC, Tytgat GA, van Eck-Smit BL, Kam B, Caron HN, van Noesel M. Upfront treatment
of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan. Pediatr Blood
Cancer 2015; 62: 1886-91.
35. Seo ES, Lee JW, Cho HW, Ju HY, Cho YS, Lee S, et al. Response-adapted consolidation
therapy strategy for patients with metastatic high-risk neuroblastoma: Results of the SMC NB2014 study. Pediatr Blood Cancer 2024; 71: e31173.
36. Kuroda R, Wakabayashi H, Araki R, Inaki A, Nishimura R, Ikawa Y, Yoshimura K, et al.
Phase I/II clinical trial of high-dose [131I] meta-iodobenzylguanidine therapy for high-risk
neuroblastoma preceding single myeloablative chemotherapy and haematopoietic stem cell
transplantation. Eur J Nucl Med Mol Imaging 2022; 49: 1574-83.
37. Kayano D, Wakabayashi H, Nakajima K, Kuroda R, Watanabe S, Inaki A, et al. High-dose 131I-
32
87 / 235
over 1 year of age. Eur J Cancer 2008; 44: 551-6.
27. Kanold J, Paillard C, Tchirkov A, Merlin E, Marabelle A, Lutz P, et al. Allogeneic or
haploidentical HSCT for refractory or relapsed solid tumors in children: toward a
neuroblastoma model. Bone Marrow Transplant 2008; 42 Suppl 2: S25-30.
28. Mastrangelo S, Rufini V, Ruggiero A, Di Giannatale A, Riccardi R. Treatment of advanced
neuroblastoma in children over 1 year of age: the critical role of 131I-metaiodobenzylguanidine
combined with chemotherapy in a rapid induction regimen. Pediatr Blood Cancer 2011; 56:
1032-40.
29. Klingebiel T, Bader P, Bares R, Beck J, Hero B, Jürgens H, et al. Treatment of neuroblastoma
stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A
pilot study. Eur J Cancer 1998; 34: 1398-402.
30. Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, et al. Is there a benefit of
131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective
evaluation of The German Neuroblastoma Trial NB97 and implications for The German
Neuroblastoma Trial NB2004. Nuklearmedizin 2006; 45: 145-51; quiz N39-40.
31. Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B, et al. Pilot study of
iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and
autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002; 20: 21429.
32. DuBois SG, Allen S, Bent M, Hilton JF, Hollinger F, Hawkins R, et al. Phase I/II study of
131
I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Br J Cancer
2015; 112: 644-9.
33. Lee JW, Lee S, Cho HW, Ma Y, Yoo KH, Sung KW, et al. Incorporation of high-dose 131Imetaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem
cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. J Hematol
Oncol 2017; 10: 108.
34. Kraal KC, Tytgat GA, van Eck-Smit BL, Kam B, Caron HN, van Noesel M. Upfront treatment
of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan. Pediatr Blood
Cancer 2015; 62: 1886-91.
35. Seo ES, Lee JW, Cho HW, Ju HY, Cho YS, Lee S, et al. Response-adapted consolidation
therapy strategy for patients with metastatic high-risk neuroblastoma: Results of the SMC NB2014 study. Pediatr Blood Cancer 2024; 71: e31173.
36. Kuroda R, Wakabayashi H, Araki R, Inaki A, Nishimura R, Ikawa Y, Yoshimura K, et al.
Phase I/II clinical trial of high-dose [131I] meta-iodobenzylguanidine therapy for high-risk
neuroblastoma preceding single myeloablative chemotherapy and haematopoietic stem cell
transplantation. Eur J Nucl Med Mol Imaging 2022; 49: 1574-83.
37. Kayano D, Wakabayashi H, Nakajima K, Kuroda R, Watanabe S, Inaki A, et al. High-dose 131I-
32
87 / 235